RxDoctor Payments Data

Steven Culp, MD

Family Medicine · Lancaster, SCNPI 1013901925

Payments from drug & device makers

$6,987in general payments, 2019–2025

Across 449 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$769
  • Amgen$673
  • Pfizer$549
  • Novartis$543
  • Bayer$450
  • Amarin Pharma, Inc.$381
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$6,955100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,987 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$653,262
Medicare patients
1,253
Services billed
17,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$125,670
OzempicSemaglutide83$95,684
EliquisApixaban88$91,729
RybelsusSemaglutide43$82,294
FarxigaDapagliflozin Propanediol64$67,259
Tresiba Flextouch U-100Insulin Degludec53$62,704
JanuviaSitagliptin Phosphate54$50,398
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$43,811
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$35,048
TrulicityDulaglutide18$32,263
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$30,373
Spiriva HandihalerTiotropium Bromide28$25,168
ShingrixVaricella-Zoster Ge/As01b/Pf105$23,484
MounjaroTirzepatide14$22,564
Tresiba Flextouch U-200Insulin Degludec24$21,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$769$177,978126 claims
Boehringer IngelheimJardiance$164$125,670108 claims
PfizerEliquis, Abrysvo$549$108,169139 claims
AstraZenecaFarxiga, Symbicort$304$87,526108 claims
Lilly USA, LLCTrulicity, Mounjaro$316$54,82732 claims
GSKTrelegy Ellipta, Shingrix$149$53,857133 claims
MerckJanuvia$127$50,39854 claims
AbbVieLinzess$173$21,60419 claims
AmgenProlia$673$19,85911 claims
Johnson & JohnsonXarelto$162$19,85218 claims
BayerKerendia$450$17,07413 claims
Astellas Pharma US IncMyrbetriq$70$15,52515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Lancaster

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →